Kymera Therapeutics, Inc. (KYMR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Kymera Therapeutics, Inc. in 2026. The next earnings report is expected on October 29, 2026.
Kymera Therapeutics beat consensus estimates in its latest earnings report, with EPS of -$0.62 beating the -$0.7126 estimate and revenue of $65 million exceeding the $32.78 million forecast by 98.3%. In the prior quarter both EPS and revenue were also ahead of expectations.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
